EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destruction
Abstract Myelomatous bone disease is a complication characterized by lytic bone lesions, reduced bone formation, bone pain, and increased fracture risk. Understanding these underlying mechanisms is crucial for developing effective therapeutic approaches. Here we show the role of enhancer of zeste ho...
Saved in:
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-025-56506-5 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|